US Patent

US9458195 — Melanocortin receptor ligands

Composition of Matter · Assigned to Ipsen Pharma SAS · Expires 2027-10-13 · 1y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that act as ligands for melanocortin receptors and their pharmaceutically-acceptable salts.

USPTO Abstract

The present invention is directed to compounds according to formula, (R 2 R 3 )-A 1 - c (A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 )-A 10 -R 1 , and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

Drugs covered by this patent

Patent Metadata

Patent number
US9458195
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-10-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Ipsen Pharma SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.